Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Change in Acquisitions & Divestments for 15 consecutive years, with $115.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 2.4% year-over-year to $115.3 million, compared with a TTM value of $686.8 million through Dec 2025, up 60.83%, and an annual FY2025 reading of $689.6 million, up 55.9% over the prior year.
  • Change in Acquisitions & Divestments was $115.3 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $101.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $240.5 million in Q2 2025 and bottomed at $13.1 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $96.6 million, with a median of $85.9 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 314.72% in 2021, then tumbled 46.4% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $38.3 million in 2021, then skyrocketed by 81.39% to $69.4 million in 2022, then soared by 92.31% to $133.5 million in 2023, then decreased by 11.48% to $118.2 million in 2024, then fell by 2.4% to $115.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ARWR at $115.3 million in Q4 2025, $101.8 million in Q3 2025, and $240.5 million in Q2 2025.